论文部分内容阅读
1例61岁男性患者,因小细胞肺癌化、放疗期间出现血小板减少,给予重组人白细胞介素-11(rhIL-11)3 mg,1次/d,皮下注射。给药第5天患者出现双下肢轻度水肿,第7天发展为重度水肿。考虑水肿与rhIL-11有关,立即停用rhIL-11,给予氢氯噻嗪、螺内酯利尿治疗。停药2 d后患者水肿逐渐消退。2个月后患者再次出现血小板减少,再给予皮下注射rhIL-11,3 mg/d,给药5 d后患者再次出现双下肢轻度水肿,停用rhIL-11,2 d后水肿消退。
A 61-year-old male patient was given subcutaneous injection of recombinant human interleukin-11 (rhIL-11) 3 mg once a day for thrombocytopenia due to small cell lung cancer and radiotherapy. On day 5, patients developed mild edema of both lower extremities and developed severe edema on day 7. Considering that edema is associated with rhIL-11, rhIL-11 is discontinued immediately and hydrochlorothiazide and spironolactone are used to treat diuresis. After 2 days of drug withdrawal edema gradually subsided. Two months later, the patient again suffered from thrombocytopenia. Then rhIL-11 was injected subcutaneously at a dose of 3 mg / d. After 5 days of administration, mild edema of both lower extremities occurred again. After rhIL-11 was discontinued, edema subsided.